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Abstract
Background: Rapid detection of bloodstream infections (BSIs) can be lifesaving. We investigated the sample processing and
assay parameters necessary for highly-sensitive detection of bloodstream bacteria, using Staphylococcus aureus as a model
pathogen and an automated fluidic sample processing – polymerase chain reaction (PCR) platform as a model diagnostic
system.
Methodology/Principal Findings: We compared a short 128 bp amplicon hemi-nested PCR and a relatively shorter 79 bp
amplicon nested PCR targeting the S. aureus nuc and sodA genes, respectively. The sodA nested assay showed an enhanced
limit of detection (LOD) of 5 genomic copies per reaction or 10 colony forming units (CFU) per ml blood over 50 copies per
reaction or 50 CFU/ml for the nuc assay. To establish optimal extraction protocols, we investigated the relative abundance
of the bacteria in different components of the blood (white blood cells (WBCs), plasma or whole blood), using the above
assays. The blood samples were obtained from the patients who were culture positive for S. aureus. Whole blood resulted in
maximum PCR positives with sodA assay (90% positive) as opposed to cell-associated bacteria (in WBCs) (71% samples
positive) or free bacterial DNA in plasma (62.5% samples positive). Both the assays were further tested for direct detection of
S. aureus in patient whole blood samples that were contemporaneous culture positive. S. aureus was detected in 40/45 of
culture-positive patients (sensitivity 89%, 95% CI 0.75–0.96) and 0/59 negative controls with the sodA assay (specificity
100%, 95% CI 0.92–1).
Conclusions: We have demonstrated a highly sensitive two-hour assay for detection of sepsis causing bacteria like S. aureus
directly in 1 ml of whole blood, without the need for blood culture.
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Introduction
Blood stream infections (BSIs) are a serious cause of morbidity
and mortality worldwide. Early diagnosis and appropriate
treatment of sepsis has been shown to decrease life-threatening
complications [1,2,3,4,5]. BSIs are usually diagnosed by perform-
ing a series of blood cultures [1]. Unfortunately, this technique is
slow, usually requiring one or more days to produce a positive
result. Nucleic acid-based amplification tests (NAATs) are
potentially more rapid and sensitive than blood cultures
[6,7,8,9]. However, even NAATs appear to have limited sensitivity
when applied to detecting bacteria directly from patient blood
samples. For this reason, most NAATs require bacteria to be
enriched in blood cultures before the cause of a BSI can be reliably
detected [10,11]. One commercially available NAAT, the
SeptiFast
TM assay (Roche Diagnostics, Indianapolis, IN), appears
to adequately detect BSI directly from non-enriched blood
samples. However, the SeptiFast
TM assay requires a total of
6 hours to complete, including 3 hours of technician hands-on
time [12]. Furthermore, the overall bacterial detection rate among
suspected sepsis patients was relatively poor and sensitivity varied
highly among different studies [13,14,15].
Most adult patients with BSI have relatively low concentrations
of bacteria in their blood [16]. Blood is also highly inhibitory to the
polymerase chain reaction (PCR) [17,18]. NAAT-based BSI assays
must therefore be highly sensitive; and the nucleic acid extraction
protocols which are used must recover as much bacterial DNA as
possible from a relatively large volume of blood. Extraction
techniques must also ensure that the DNA which is recovered is
inhibitor-free and of high purity. These requirements increase the
cost and complexity of NAAT-based BSI assays. The development
of the GeneXpertH sample processing and PCR system (Cepheid,
Sunnyvale, CA) suggested some simple solutions to these issues.
The GeneXpertH system uses a filter-capture approach to isolate
bacteria from relatively large blood volumes. The internal fluidics
of the system’s sample processing cartridge permits extensive
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it possible to increase assay sensitivity through the use of nested
PCR without the risk of amplicon cross contamination.
Several critical questions need to be resolved before sample
processing and amplification systems can be used to optimally
detect BSI directly from patient blood. First, what analytic
sensitivity is required to detect most cases of BSI? Prior studies
examining the average number of bacterial colony forming units
(CFU) per ml of blood in BSI patients cannot directly answer this
question since DNA from non-viable bacteria may also be present
in blood. Second, what blood components contain the maximum
signal for BSI? The DNA target of a PCR assay could presumably
be present in blood as free plasma DNA, or it could be present
within intact (viable or non-viable) bacteria that are either freely
floating in blood or concentrated within WBC. Extraction
protocols would clearly vary depending on the requirements to
capture DNA from these different blood compartments. To our
knowledge, no study has yet examined the blood of BSI patients to
see which blood compartment contains the maximum number of
bacterial DNA targets for a PCR assay. The answers to these
questions are of critical importance for a good assay design.
Staphylococcus aureus is responsible for a significant proportion of
BSIs [19,20]. In this study, we have used S. aureus as a model
pathogen to investigate assay and blood processing parameters
required to achieve maximal sensitivity for NAAT-based BSI
detection. In the process, we designed and tested a highly sensitive
assay to detect S. aureus directly from patient blood that used a
customized GeneXpertH platform. To our knowledge, this is the
first study to systematically determine the presence of bacteria in
different blood components. This is also the first time a completely
automated hands-free integrated sample processing and PCR
based detection method has been successfully demonstrated to
detect S. aureus directly in patient blood samples, without the need
for culture.
Methods
Ethics statement
The study was approved by University of Medicine and
Dentistry of New Jersey (UMDNJ)-Institutional review board
(IRB) with the IRB protocol number: 0120080060 as ‘‘exempt’’
#4 because the tested samples were de-identified and would
normally have been discarded. Informed consent of the study
subjects was not required due to the nature of the samples.
Preparation of bacterial cells and genomic DNA for
analytical experiments
S. aureus ATCC 25923 was used for all analytic studies. The
initial inoculum was prepared by growing the bacteria at 37uCi n
Luria-Bertini (LB) broth (BD, Sparks, MD) for 16–18 h. Serial
dilutions were made in LB broth and plated on brain heart
infusion (BHI) agar to evaluate the colony forming units (CFU) per
milliliter; and the same dilutions were used in analytical
experiments. Genomic DNA from S. aureus was purified using
the GenElute bacterial genomic DNA kit (Sigma-Aldrich, St.
Louis, MO). Genomic DNA from all bacteria tested for specificity
was isolated by boiling at 90uC for 15 min using InstaGene Matrix
reagent (Biorad, Hercules, CA). The DNA in the supernatant was
transferred to a fresh tube and stored at 220uC until further use.
Optimization of the PCR assays
Two hemi-nested PCR assays were developed to test S. aureus
detection, a ‘‘short amplicon’’ (100–200 bp) assay targeting the S.
aureus nuc gene and a ‘‘shorter amplicon’’ (,100 bp) assay
targeting the S. aureus sodA gene. Gene specific primers were
designed using the PrimerSelect (DNASTAR Lasergene ver 8.1.3)
and/or Primer3 [21] programs and the molecular beacons to the
inner PCR fragment were designed using the Mfold web server
[22] (Data S1). Real-time nested amplification targeting nuc and
sodA gene was performed in a GeneXpertH cartridge controlled by
GeneXpertH instrument. For the nuc assay, the hemi-nested PCR
reaction consisted of two sets of primers designed to sequentially
amplify an outer 182 bp and an internal 128 bp amplicon (Data
S1). For the sodA assay, the nested PCR reaction consisted of two
sets of primers designed to sequentially amplify an outer 161 bp
and an inner 79 bp amplicon. For both assays, the inner PCR
reaction mix consisted of 16 PCR buffer (10 mM Tris-HCl,
pH 8.3, 50 mM KCl and 0.001% (w/v) gelatin) with 4 mM
MgCl2, 250 mM of each nucleotide (deoxynucleoside triphos-
phate), 0.5 mM of each primer (forward and reverse), 4 ng of the
molecular beacon and 4 U of Jumpstart Taq DNA polymerase
(Sigma Aldrich, St. Louis, MO). The outer PCR reaction mix
consisted of the same components, except for MgCl2 which was
added at 3 mM and 3.5 mM concentrations for the nuc and sodA
PCR assays, respectively. The outer assays also omitted the
molecular beacons. The outer PCR was performed in a final
volume of 80 ml, which included 1 ml of genomic DNA or 40 mlo f
bacterial lysate, depending on the target being amplified. PCR was
performed using the thermal cycling conditions described in Data
S1. To examine the effect of amplicon size on the LOD, a second
set of sodA primers were designed to amplify a 79 bp region within
the 161 bp sodA amplicon (Data S1). The primers were designed to
have a Tm similar to the primers amplifying the larger amplicon.
The two sodA assays were compared using identical PCR
conditions (Data S1) without nesting.
Collection and storage of clinical patient blood samples
To obtain blood samples from patients with bacteremia, k2-
EDTA anticoagulated blood tubes submitted for complete blood
counts (CBCs) to the Department of hematology at the University
of Medicine and Dentistry of New Jersey (UMDNJ) University
Hospital (UH) were saved in a refrigerator at 4uC for 4–6 days
after they had been used for routine purposes and would normally
have been discarded. These tubes usually had 1 to 4 ml of blood
remaining. With the help of the UH clinical microbiology
laboratory, patients with S. aureus positive blood cultures were
identified and matched with the tubes stored at the UH
hematology laboratory based on patient identification numbers.
Patient identifiers were removed before the samples were brought
to the research laboratory for testing by the GeneXpert system.
Culture-negative control samples were similarly collected after
confirming that the patient had not had positive blood cultures
during the CBC blood collection period. For use in analytical
experiments, culture-negative k2-EDTA blood was collected as
described above and blood from individual tubes was pooled to
obtain larger volumes. An aliquot was tested by PCR to confirm
the absence of detectible S. aureus. The study was approved by the
UMDNJ Institutional review board.
Blood sample processing
For whole blood studies, one ml of CBC blood was processed in
a GeneXpertH cartridge containing a filter (the filter-based (FB)
cartridge) to capture intact bacteria from clinical samples, as
follows. Different chambers within empty FB cartridges were
manually filled with PCR reaction mix or sample processing
buffers. A blood sample was added to a FB cartridge’s sample
chamber, and the cartridge was then inserted into a GeneXpertH
system module. The sample was then processed within the
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protocol using customized fluidics software. The automated
sample processing steps of the assay protocol are shown in
Figure 1. A link showing the fluidics of a similar assay is available
at http://www.youtube.com/watch?v=HF6HzlqOhkg. The
blood sample was first mixed with 1:1 8% NaOH; the lysed
blood was then passed through the internal cartridge filter; the
filter-captured bacteria were then extensively washed with a Tris
(50 mM)- EDTA (0.1 mM) –Tween (0.1%) (TET) buffer, pH 8.4;
glass beads present in the filter chamber were then agitated by an
ultrasonic horn to lyse the bacterial cells. The liberated DNA was
washed through the filter into a collection chamber and then
mixed with the outer PCR mix. For a 1 ml blood sample, all of the
bacteria present in the sample were captured on the FB cartridge
filter. After cell lysis, bacterial DNA was eluted-off of the filter and
mixed approximately 1:1 with PCR reagents. Approximately 30%
of the total eluted DNA was then moved into the PCR tube which
is integrated into the FB cartridge for PCR amplification and
detection. PCR was then performed as described above. To
perform nested PCR, the first PCR reaction included a step where
the outer PCR amplicon was withdrawn from the integrated PCR
and approximately 10% was then mixed with the inner PCR
buffer. Real-time PCR of the inner amplicon was performed. A
positive signal was indicated by the real-time cycles vs fluorescence
units curve for the selected fluorophore. The cycle threshold (Ct)
was calculated by the GeneXpertH software.
Analytical sensitivity and specificity tests
Analytical sensitivity of both the short amplicon nuc PCR and
the shorter amplicon sodA PCR assays was determined using
genomic DNA and bacterial cells. Genomic DNA copy number
was estimated based on the molecular weight of the S. aureus
genome (2.7–2.8 mbp) using the copy number calculator on URI
Genomics and Sequencing Center website (http://www.uri.edu/
research/gsc/resources/cndna.html), and test sample were created
by diluting stock DNA in water.
To determine the limit of detection of S. aureus in whole blood,
the cells were prepared from pre-quantified cell stock and serially
diluted as explained before. Serial dilutions were made in LB
broth and spiked into culture negative whole blood to achieve cell
concentrations ranging from 1 CFU/ml through 100 CFU/ml.
One ml of this sample was loaded into chamber 3 of the FB
cartridge. The nuc and sodA assays were performed side-by-side to
compare assay performance in replicates of six per target
concentration. The assay was scored based on the number of
positive assays per target concentration.
Assay specificity was examined in the GeneXpert system as a
nested reaction by spiking outer PCR mix with 1 ng of genomic
DNA from coagulase negative staphylococci (S. epidermidis, S.
hominis, S. capitis, S. cohnii, S. haemolyticus, S. hominis, S. lugdunensis, S.
sciuri, S. schleiferi, and S. warneri), Escherichia coli, Klebsiella pneumoniae,
and Serratia marcescens clinical isolates. Assay specificity was further
assessed by testing the outer and inner primers separately in PCR
reactions of DNA extracted from Acinetobacter baumanii, Bacillus
subtilis, B. cereus, Campylobacter jejuni, Citrobacter freundii, Corneybacterium
pseudodiptheriae, Enterobacter cloacae, enterococcus avium, E. faecalis, E.
faecium, Klebsiella oxytoca, Haemophilus influenzae, Proteus mirabilis, P.
vulgaris, Streptococcus agalactiae, S. pneumoniae and Staphylococcus
epidermidis using the LightCycler480 (Roche, Indianapolis, IN) as
a detection system. All samples were obtained from UMDNJ’s UH
Microbiology laboratory. S. aureus ATCC 25923 genomic DNA
was used as positive control in these studies.
Relative bacterial abundance in different blood
components
BSI-causing bacteria can theoretically exist in three blood
components: 1) as intact bacteria that are free within patient
blood, 2) as free DNA in patient plasma (presumably from lysed
bacteria), or 3) as intact bacteria that are trapped in WBCs. The
utility of a particular sample processing technique to detect BSI
may depend greatly on the relative amounts of target in each of
these components. Patient blood (in k2-EDTA tubes) samples,
which were culture positive for S. aureus were obtained as described
above. Most CBC tubes used in this experiment contained a total
of 3–4 ml blood. These tubes were divided into three fractions of
1 ml each and any remaining blood was discarded or used for
other experiments. One fraction was processed for plasma
isolation, the second for WBC isolation and the third was used
as whole blood (Figure 2). An occasional CBC tube contained only
2 ml of blood. In this case, the blood was divided into 2 ml
fractions and two out of the three blood components were tested.
To test for intact bacteria in whole blood, one ml was processed in
the FB cartridge as described above. To test for free bacterial
DNA in plasma, one ml of blood was centrifuged at 12006g for
15 min and the supernatant was transferred to a sterile
EppendorfH tube. The supernatant was passed through a 0.45 m
syringe filter (Corning Inc, Corning, NY) and the filtrate (350–
500 ml) was collected in a sterile tube [23], to avoid carry-over of
any WBCs or free cells. The volume was then increased up to
700 ml with sterile phosphate buffered saline (PBS, pH 7.4) and
mixed 1:1 with lysis buffer (containing 1:1 ethanol and 5 M GTC
in Tris buffer, pH 8.0) and a bead (0.75 mg) of proteinase K. The
mix was vortexed well and the whole (1400 ml) preparation was
added to the sample loading slot in a column based resin (CBR)
cartridge, which is designed to capture free DNA rather than
intact cells. The captured DNA was eluted with Tris EDTA
Tween (TET) buffer.
To test for bacterial cells in WBC, WBCs were extracted from
one ml of blood using a whole blood column in conjugation with
CD45+ microbeads (Miltenyi biotech, Auburn, CA). The labeling
Figure 1. Flow diagram of the fluidic steps involved in sample
processing and PCR amplification for target genes.
doi:10.1371/journal.pone.0031126.g001
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turer’s recommendations. Also as recommended, the bound
WBCs were extracted from the column in 5 ml of blood
separation buffer. The total cells were evaluated microscopically
by mixing a 100 ml of this opaque-white elute with 100 mlo f
trypan blue and 10 ml was loaded on to a haemocytometer
(Reichert, Buffalo, NY). No significant concentration of red blood
cells (RBC) was observed. The whole 5 ml of WBCs were
centrifuged at 12006 g for 15 min [24], the supernatant was
discarded and the pellet was resuspended in 1 ml of sterile PBS
and then processed in the GenexpertH system using the same
software protocol as for whole blood (iNaOH) (Figure 2). A cycle
threshold (Ct) cut-off of 40 was set based on the analytical LOD
experiments.
Detection of S. aureus in patient blood samples
Whole blood from a total of 96 patients confirmed to be positive
for S. aureus by blood culture, were selected and stored as described
before. One-ml of the blood sample was tested directly in the
GeneXpert FB cartridge system, using both nuc and sodA assay
following the iNaOH blood sample processing methodology
described in Figure 1.
Statistics
Standard statistical analysis (average, standard deviation and t-
test) was performed using Microsoft Excel 2000 for Windows.
Confidence interval levels were calculated using the online clinical
calculator 1 available on the website http://faculty.vassar.edu/
lowry/clin1.html. Linear regression model to fit percent positives
curves was performed using GraphPad Prism ver 5.04 for
windows, GraphPad software, San Diego, California, USA,
www.graphpad.com.
Results
Analytical sensitivity and specificity
Many NAAT detection assays are considered highly-sensitive if
they have a limit of detection (LOD) of less than 50 targets per ml
[25]. We postulated that even this high degree of sensitivity might
not be sufficient to detect BSI directly from patient blood. Two
different assays targeting the nuc gene, a hemi-nested PCR
producing a short amplicon (128 bp), and a second assay targeting
sodA in a fully nested PCR with a shorter amplicon (79 bp) were
tested analytically. In tests of genomic DNA (Figure 3A), both
assays could detect 50 genomic copies per reaction 100% of the
time; however, the sodA assay was clearly more sensitive as it could
detect 5 genomes 100% of the time versus 60% of the time for the
nuc assay. The sodA assay was also confirmed to be more sensitive
in tests using S. aureus cells spiked into blood (Figure 3B). The
increased sensitivity of this assay is likely due to its very small
amplicon size, since a sodA assay targeting the same region but
producing larger amplicons similar to the nuc assay had a
decreased limit of detection similar to the more poorly-performing
nuc assay (Data S2). Both nuc and sodA nested PCR assays were
100% specific when tested against genomic DNA from all of the
control bacteria mentioned in the materials and methods section.
Relative bacterial abundance in different blood
components
We investigated the relative distribution of bacteria in three
blood components (whole blood, WBC and plasma) in patients
with S. aureus BSI using the nuc and sodA assays. Patient blood
Figure 2. Blood components study processing schematic. CBC
blood from patients with blood culture positive for S. aureus was
divided into 1 ml each for detection of S. aureus load in plasma, white
blood cells (WBCs) and whole blood. Plasma was processed using a
column based resin (CBR) cartridge. WBCs and whole blood was
processed in a filter based (FB) cartridge.
doi:10.1371/journal.pone.0031126.g002
Figure 3. Analytical sensitivity of the nuc and sodA assays for
the detection of Staphylococcus aureus genomic DNA (A) and S.
aureus cells spiked in blood (B).
doi:10.1371/journal.pone.0031126.g003
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(CBC), who had a contemporaneous blood sample that was
culture positive for S. aureus were selected and fractionated into
each of the three blood components [or randomly into two
components if sufficient blood volume ($3 ml) was not available].
The components were then tested either with the nuc (Figure 4A)
or sodA assay (Figure 4B) to determine whether S. aureus could be
detected, and to compare the relative amounts of target in each
component. Samples with Ct.40 were considered negative.
In our studies, we found that intact bacteria present in whole
blood accounted for the largest number of samples that were
positive for S. aureus (45% tested with the nuc assay and 90% tested
with the sodA assay). Intact bacteria within WBCs were the next
most likely to test positive (40% and 71%, respectively with nuc and
sodA assays), while free DNA in plasma was the least likely to test
positive (36% and 62.5%, respectively). Importantly, the whole
blood fraction also produced earlier Ct values for positive assays
than the other components, with median Ct values of 32.9, 39.3
and 37.5 for whole blood, WBCs and plasma respectively, with the
nuc assay (Figure 4A). Similarly, the more sensitive sodA assay
produced median Ct values of 25.1 for whole blood compared to
26.5 for WBCs and 28.3 for plasma (Figure 4B).
Our whole blood components extraction protocol recovered
intact bacterial cells present within WBCs as well as free bacteria
that were not cell-associated. We observed higher percent positives
in whole blood compared to WBCs. Subtracting the median ct
value from the whole blood samples from that of WBCs yielded a
difference of 4.6 median Ct values (with nuc assay) indicating that
.10 times more intact bacteria were present in blood outside of
WBCs than within WBC. We also observed higher percent
positives in whole blood compared to WBCs. These results
strongly suggest that bacterial DNA largely exists in intact
extracellular bacteria in patients with S. aureus BSI. Sample
processing protocols that focus on extracting DNA from these
intact bacteria in whole blood are likely to be the most successful.
BSI detection in patient blood samples
Our blood components studies strongly suggested that the
Cepheid FB cartridge was well-suited for recovering S. aureus from
the blood of patients with S. aureus BSI. We used this system to
examine the performance of the nuc and sodA assays for S. aureus
BSI detection compared to blood culture. A total of 96 k2-EDTA
blood samples from patients with S. aureus positive blood cultures
and 88 k2-EDTA blood samples from patients who were culture-
negative for S. aureus were collected. Fifty-one positive and 29
negative samples were tested with the nuc assay; and 45 positive
and 59 negative samples were tested with the sodA assay (Table 1).
The nuc assay detected S. aureus in 29/51 (sensitivity 57%, 95% CI
0.42–0.7) patients with S. aureus BSI and excluded S. aureus in 28/
29 who did not have a documented S. aureus BSI (specificity 96.5%,
CI 0.88–0.99), including 15 patients who were culture positive for
other bacterial species. The one nuc positive sample had a Ct
value of 36 and was confirmed to have S. aureus by DNA
sequencing.
The sodA assay performed significantly better than the nuc assay
(P,0.05). The assay was positive in 40/45 (89%, 95% CI 0.75–
0.96) blood samples of patients with S. aureus BSI and negative in
59/59 (100%, 95% CI 0.92–1) patients without S. aureus BSI
including 20 patients who were culture-positive for other bacterial
species. Overall the sodA assay detected 32% more cases of S. aureus
BSI than the nuc assay (p,0.05). These results indicate that
efficient BSI detection requires assays with an analytic sensitivity of
,10 CFU per ml and when combined with the GeneXpert FB
cartridge sample processing system, can result in very high case
detection rates.
Discussion
This study investigates the assay parameters required to
sensitively detect target bacteria in patients with S. aureus BSI.
We discovered that both intact extracellular and intracellular
bacteria in blood contribute to the majority of the positive assay
signal. Extraction protocols must target these bacteria for optimal
sensitivity. Protocols that retain WBCs or extract free DNA from
plasma are unlikely to further increase assay sensitivity. This
finding is important because WBCs contain human genomic DNA
which may inhibit PCR assays [18,26]. Free plasma DNA may be
quite complex and laborious to extract.
We also determined that the PCR assays for BSI identification
must have a very high sensitivity in the test matrix (blood). The nuc
assay had a LOD of at least 50 CFU per ml blood. This LOD
would normally indicate a highly-sensitive assay. However, we
determined that a LOD of 50 CFU per ml was insufficient to
reliably detect S. aureus in the blood of BSI patients. Instead, a
LOD,10 CFU per ml was required. We achieved the ultra-high
sensitivity of the sodA assay by reducing the assay amplicon to the
smallest size possible and by using a fully nested-PCR protocol.
Even the moderately larger nuc amplicon had decreased sensitivity
compared to the sodA assay. It should be noted that both nuc and
Figure 4. Detection of bacterial load in different blood
components by nuc (A) and sodA (B) assays. Each Ct data point
(open circles) indicates individual patient samples tested in each blood
component (one color for each patient sample). The horizontal line
indicates median Ct values. Solid color bars in green (nuc assay) and
orange (sodA assay) represent the corresponding % positive on the
secondary axis. An ‘‘n’’, indicates the number of samples analyzed. WBC,
indicates white blood cells.
doi:10.1371/journal.pone.0031126.g004
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Thus, the increase in the sensitivity of the sodA assay can likely be
attributed to the decreased amplicon size. PCR assays designed
with relatively small amplicon sizes are known to perform better
than larger amplicons, because the PCR kinetics favors smaller
amplicons [28,29,30,31].By shortening an amplicon size from
84 bp to 50 bp Sikora et al., [32] improved detection rate of cell-
free fetal DNA even in low template samples (early pregnancy).
Our study further supports this conclusion and may serve as a
guide to designers of BSI detection assays.
The sodA assay detected S. aureus in BSI patients directly from
1 ml of patient blood with a diagnostic sensitivity of nearly 90%. It
is likely that the sensitivity of our assay could be further improved
by increasing the sample volume. Our results are particularly
remarkable given that our study was not limited to patients with
overt sepsis. Septic patients might be expected to have relatively
higher concentrations of bacteria in their blood. Rather, we tested
all patients who had positive blood cultures for S. aureus for any
reason. It would be interesting to analyze diagnostic sensitivity
according to the disease state of the patients studied. Unfortu-
nately, the nature of our study design (which used de-identified
samples) precluded this possibility. A prospective trial to study this
question is needed; however, it would likely be very expensive,
since most enrolled subjects would be culture negative.
S. aureus is one of the most common causes of bloodstream
infections. We selected this target organism because of its medical
importance and because a relatively large number of patients with
S. aureus BSI were available at our institution. The SeptiFast assay
(Roche, Indianapolis, IN) is the only commercially available
method designed to directly detect bacteria from blood. Our
methodology performed equally well or better than published
reports using SeptiFast assay. Detection concordance for SeptiFast
assay compared to blood culture has varied highly for individual
studies, ranging from 42% [33] to 80% [14,34] for the detection of
any bacteria. Genomic DNA extraction for SeptiFast assay is
reported to be laborious and recent studies have used alternative
methods of sample processing to reduce the assay time from 6.54 h
to 3.56 h (Regueiro et al., 2011). Our assay demonstrated 89%
sensitivity with S. aureus and took about 2 h to complete with
hands-on time of less than 2 min. This assay format can be easily
adapted to detect other bacterial causes of BSI in a uniplex or a
multiplex PCR platform.
In conclusion, we have identified the assay parameters required
for highly sensitive BSI detection that can detect bacteria causing
BSI directly from 1 ml of whole blood within 2 h. Although our
study focused on S. aureus detection, it is likely to be more widely
applicable to detection of other causes of bacterial sepsis. The
automatic system which we used can detect six different colors,
thus it is currently limited to detecting six different probes and
targets in a single assay. However, more highly multiplexed
approaches are being developed which can potentially expand the
ability of a single PCR reaction to detect and distinguish among
hundreds of different targets [35]. If applicable to an automated
system, it is possible that our approach could detect all medically
relevant causes of BSI in a single test. This approach uses an
automated hands-free system that minimizes manual technical
errors and potentially reduces cost. These results could also be
directly employed for developing a point of care diagnostic system.
Our approach may lead to life saving diagnostic assays that rapidly
identify the infecting pathogen in patients with BSI and sepsis,
enabling more rapid diagnosis and treatment of these life-
threatening conditions.
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